MiMedx Group Management
Management criteria checks 4/4
MiMedx Group's CEO is Joe Capper, appointed in Jan 2023, has a tenure of 2.42 years. total yearly compensation is $1.39M, comprised of 54% salary and 46% bonuses, including company stock and options. directly owns 0.36% of the company’s shares, worth $3.10M. The average tenure of the management team and the board of directors is 2.7 years and 4.8 years respectively.
Key information
Joe Capper
Chief executive officer
US$1.4m
Total compensation
| CEO salary percentage | 53.96% |
| CEO tenure | 2.4yrs |
| CEO ownership | 0.4% |
| Management average tenure | 2.7yrs |
| Board average tenure | 4.8yrs |
Recent management updates
Recent updates
Some Shareholders Feeling Restless Over MiMedx Group, Inc.'s (NASDAQ:MDXG) P/E Ratio
Apr 17
MiMedx Group (NASDAQ:MDXG) Seems To Use Debt Rather Sparingly
Mar 27Some May Be Optimistic About MiMedx Group's (NASDAQ:MDXG) Earnings
Mar 05Here's Why MiMedx Group (NASDAQ:MDXG) Has Caught The Eye Of Investors
Feb 22We Think MiMedx Group (NASDAQ:MDXG) Can Manage Its Debt With Ease
Dec 23We Ran A Stock Scan For Earnings Growth And MiMedx Group (NASDAQ:MDXG) Passed With Ease
Nov 21There's No Escaping MiMedx Group, Inc.'s (NASDAQ:MDXG) Muted Earnings Despite A 27% Share Price Rise
Nov 06
HELIOGEN's Launch And Scientific Breakthroughs Promise Growth Amid Reimbursement And Legal Challenges
The launch of HELIOGEN and strategic expansions in the surgical market underscore innovation and efforts to boost revenue through new market penetration and customer loyalty.MiMedx Group, Inc.'s (NASDAQ:MDXG) Shares Bounce 27% But Its Business Still Trails The Industry
May 21We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt
May 14Improved Revenues Required Before MiMedx Group, Inc. (NASDAQ:MDXG) Shares Find Their Feet
Mar 27We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt
Jan 05MiMedx Group, Inc. (NASDAQ:MDXG) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
Dec 18Is MiMedx Group (NASDAQ:MDXG) Using Debt In A Risky Way?
Aug 08Does MiMedx Group (NASDAQ:MDXG) Have A Healthy Balance Sheet?
Apr 22Health Check: How Prudently Does MiMedx Group (NASDAQ:MDXG) Use Debt?
Dec 20CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | US$40m |
| Dec 31 2024 | US$1m | US$750k | US$42m |
| Sep 30 2024 | n/a | n/a | US$79m |
| Jun 30 2024 | n/a | n/a | US$79m |
| Mar 31 2024 | n/a | n/a | US$68m |
| Dec 31 2023 | US$21m | US$678k | US$56m |
Compensation vs Market: Joe's total compensation ($USD1.39M) is below average for companies of similar size in the US market ($USD3.98M).
Compensation vs Earnings: Joe's compensation has been consistent with company performance over the past year.
CEO
Joe Capper (61 yo)
Mr. Joseph H. Capper, also known as Joe, is an Independent Director at Anika Therapeutics, Inc since May 28, 2024. He serves as Chief Executive Officer and Director of MiMedx Group, Inc. since January 30,...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.4yrs | US$1.39m | 0.36% $ 3.1m | |
| Chief Financial Officer | 1.9yrs | US$2.39m | 0.021% $ 184.6k | |
| Executive VP & COO | 2.4yrs | US$2.29m | 0.13% $ 1.1m | |
| General Counsel & Chief Administrative Officer | 5.5yrs | US$2.40m | 0.28% $ 2.4m | |
| Chief Commercial Officer | 1yr | US$3.99m | 0.060% $ 520.9k | |
| Head of Investor Relations | 2.7yrs | no data | no data | |
| Senior VP & Chief Compliance Officer | 2.2yrs | no data | no data | |
| Vice President of Investor Relations & Corporate Strategic Communications | no data | no data | no data | |
| Chief Human Resources Officer | 2.9yrs | no data | no data | |
| Chief Medical Officer | 6.5yrs | no data | no data | |
| President of Regenerative Medicine & Biologics Innovation | 4.8yrs | US$1.74m | no data | |
| Vice President of Global Regulatory Affairs | 12.2yrs | US$198.47k | no data |
Experienced Management: MDXG's management team is considered experienced (2.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.4yrs | US$1.39m | 0.36% $ 3.1m | |
| Independent Preferred Director | 4.9yrs | no data | 0.00034% $ 2.9k | |
| Independent Director | 6yrs | US$234.37k | 0.11% $ 941.6k | |
| Independent Preferred Director | 4.9yrs | US$225.87k | 0.10% $ 890.5k | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Member of Regenerative Medicine Scientific Advisory Board | 2.9yrs | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Independent Director | 4.6yrs | US$232.50k | 0.088% $ 761.2k | |
| Independent Director | 6yrs | US$235.87k | 0.24% $ 2.1m | |
| Member of Regenerative Medicine Scientific Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Member of Regenerative Medicine Scientific Advisory Board | 2.9yrs | no data | no data |
Experienced Board: MDXG's board of directors are considered experienced (4.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/18 12:22 |
| End of Day Share Price | 2025/06/18 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MiMedx Group, Inc. is covered by 11 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Wittes | Brean Capital |
| William Plovanic | Canaccord Genuity |
| Ross Osborn | Cantor Fitzgerald & Co. |